Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science Officer-Virology Iain Dukes – Executive Chairman Bruce Mackle – LifeSci Advisors Conference Call Participants Operator Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode.
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demonstrated safety and tolerability, and maintained blood levels above the EC90 for more than 23 days in a Phase I clinical trial.
Traws Pharma, Inc. (NASDAQ:TRAW ) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Participants Chong Liu - Ladenburg Thalmann Operator Operator Ladies and gentlemen, welcome to Traws Pharma, Inc. Corporate Update Call. At this time all participants are in a listen-only mode.
21 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
13 May 2025 Date | | - Cons. EPS | 22.44 EPS |
31 Mar 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
15 Aug 2024 Date | | - Cons. EPS | - EPS |
21 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
13 May 2025 Date | | - Cons. EPS | 22.44 EPS |
31 Mar 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
15 Aug 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Iain D. Dukes DPHIL, CEO | NASDAQ (CM) Exchange | 68232V884 Cusip |
US Country | 6 Employees | - Last Dividend | 23 Sep 2024 Last Split | - IPO Date |
Traws Pharma, Inc. is a clinical stage biopharmaceutical company with a primary focus on developing oral small molecule product candidates. These candidates are aimed at treating respiratory viral diseases and cancer. Originally operating under the name Onconova Therapeutics, Inc., the company underwent a name change to Traws Pharma, Inc. in April 2024. Since its incorporation in 1998, Traws Pharma has been dedicated to advancing a portfolio of novel therapies designed to tackle treatment resistance in these critical areas. Headquartered in Newtown, Pennsylvania, Traws Pharma leverages its expertise in drug development to combat some of the most challenging diseases facing the medical community today.